Court Dismisses Privacy Claims Against IQVIA in Rose v. IQVIA Holdings Inc.
A federal court dismissed privacy-related claims against IQVIA regarding its operation of Drugs.com, citing the plaintiffs' failure to specify their search history.
Stocks · News reference
IQVIA projected that U.S. peak annual sales for products utilizing GENFIT's technology could exceed $1.5 billion by 2033.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
A federal court dismissed privacy-related claims against IQVIA regarding its operation of Drugs.com, citing the plaintiffs' failure to specify their search history.
Rothschild & Co Redburn has increased its price target for IQVIA Holdings Inc. from $287 to $299.
Truist has increased its price target for IQVIA Holdings Inc. while maintaining a Buy rating on the stock.
IQVIA Holdings Inc. announced its third-quarter 2026 financial results, reporting revenue of $4.43 billion and adjusted earnings per share of $3.34.
Filed: 2026-10-27 AccNo: 0001628280-26-067406 Size: 424 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits